(Q33375800)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1

Kristie A Blum

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

5

Bruce D Cheson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Jeffrey L Johnson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Donna Niedzwiecki

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

George P Canellos

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

1313-1319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells.

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

The molecular and cellular origins of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411458

10.1080/10428190701411458

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17613759%20AND%20SRC:MED&resulttype=core&format=json

release_s4z4cwfr6vfpdhpimdue4kih4m

1 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/s4z4cwfr6vfpdhpimdue4kih4m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference